382 related articles for article (PubMed ID: 12387035)
41. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Brown DL; Brillon D
J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
[TBL] [Abstract][Full Text] [Related]
42. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
43. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
[TBL] [Abstract][Full Text] [Related]
44. [Current and future aspects of oral antidiabetic agents in type 2 diabetes].
Rybka J
Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869
[TBL] [Abstract][Full Text] [Related]
45. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
46. [Indication and side effect of alpha glucosidase inhibitor].
Katahira H; Ishida H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():399-408. PubMed ID: 12387025
[No Abstract] [Full Text] [Related]
47. Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
Boccuzzi SJ; Wogen J; Fox J; Sung JC; Shah AB; Kim J
Diabetes Care; 2001 Aug; 24(8):1411-5. PubMed ID: 11473078
[TBL] [Abstract][Full Text] [Related]
48. New oral therapies for type 2 diabetes.
Purnell JQ; Hirsch IB
Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013
[TBL] [Abstract][Full Text] [Related]
49. Type 2 diabetes management: a comprehensive clinical review of oral medications.
Quillen DM; Kuritzky L
Compr Ther; 2002; 28(1):50-61. PubMed ID: 11894443
[TBL] [Abstract][Full Text] [Related]
50. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Wolffenbuttel BH; van Haeften TW
Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
[TBL] [Abstract][Full Text] [Related]
51. Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Hayashi Y; Miyachi N; Takeuchi T; Takeuchi Y; Kamiya F; Kato T; Imaeda K; Okayama N; Shimizu M; Itoh M
Diabetes Obes Metab; 2003 Jan; 5(1):58-65. PubMed ID: 12542726
[TBL] [Abstract][Full Text] [Related]
52. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
53. [Diabetes mellitus].
Kawano M; Kanazawa Y
Nihon Rinsho; 2000 Feb; 58(2):421-5. PubMed ID: 10707569
[TBL] [Abstract][Full Text] [Related]
54. Oral agent therapy in the treatment of type 2 diabetes.
Feinglos MN; Bethel MA
Diabetes Care; 1999 Apr; 22 Suppl 3():C61-4. PubMed ID: 10189564
[No Abstract] [Full Text] [Related]
55. Type 2 diabetes therapy. A pathophysiologically based approach.
Mayerson AB; Inzucchi SE
Postgrad Med; 2002 Mar; 111(3):83-4, 87-92, 95. PubMed ID: 11912999
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological management of type 2 diabetes mellitus: an update.
El-Kaissi S; Sherbeeni S
Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
[TBL] [Abstract][Full Text] [Related]
57. Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Weissman P
Am J Cardiol; 2002 Sep; 90(5A):42G-50G. PubMed ID: 12231078
[TBL] [Abstract][Full Text] [Related]
58. [Combined therapy with insulin and alpha-glucosidase inhibitor].
Watanabe K; Kawamori R
Nihon Rinsho; 1997 Nov; 55 Suppl():261-6. PubMed ID: 9434478
[No Abstract] [Full Text] [Related]
59. [Insulin sensitizer drugs--review].
Yamanouchi T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():409-15. PubMed ID: 12387026
[No Abstract] [Full Text] [Related]
60. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
